annual EBITDA:
-$129.23M-$60.23M(-87.28%)Summary
- As of today (June 17, 2025), EYPT annual EBITDA is -$129.23 million, with the most recent change of -$60.23 million (-87.28%) on December 31, 2024.
- During the last 3 years, EYPT annual EBITDA has fallen by -$79.08 million (-157.69%).
- EYPT annual EBITDA is now -1140.72% below its all-time high of $12.42 million, reached on June 30, 2010.
Performance
EYPT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$48.34M-$7.51M(-18.40%)Summary
- As of today (June 17, 2025), EYPT quarterly EBITDA is -$48.34 million, with the most recent change of -$7.51 million (-18.40%) on March 31, 2025.
- Over the past year, EYPT quarterly EBITDA has dropped by -$15.32 million (-46.40%).
- EYPT quarterly EBITDA is now -329.97% below its all-time high of $21.02 million, reached on September 30, 2014.
Performance
EYPT quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$148.59M-$15.32M(-11.50%)Summary
- As of today (June 17, 2025), EYPT TTM EBITDA is -$148.59 million, with the most recent change of -$15.32 million (-11.50%) on March 31, 2025.
- Over the past year, EYPT TTM EBITDA has dropped by -$66.81 million (-81.71%).
- EYPT TTM EBITDA is now -1296.63% below its all-time high of $12.42 million, reached on June 30, 2010.
Performance
EYPT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
EYPT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -87.3% | -46.4% | -81.7% |
| 3 y3 years | -157.7% | -153.3% | -151.9% |
| 5 y5 years | -169.2% | -347.8% | -260.2% |
EYPT EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -157.7% | at low | -286.8% | at low | -151.9% | at low |
| 5 y | 5-year | -264.1% | at low | -3632.8% | at low | -386.6% | at low |
| alltime | all time | -1140.7% | at low | -330.0% | +11.7% | -1296.6% | at low |
EYPT EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$48.34M(+18.4%) | -$148.59M(+11.5%) |
| Dec 2024 | -$129.23M(+87.3%) | -$40.83M(+41.0%) | -$133.26M(+25.3%) |
| Sep 2024 | - | -$28.95M(-5.0%) | -$106.34M(+18.3%) |
| Jun 2024 | - | -$30.46M(-7.7%) | -$89.88M(+9.9%) |
| Mar 2024 | - | -$33.02M(+137.5%) | -$81.77M(+18.5%) |
| Dec 2023 | -$69.00M(-28.6%) | -$13.90M(+11.3%) | -$69.00M(-29.2%) |
| Sep 2023 | - | -$12.50M(-44.1%) | -$97.43M(-4.5%) |
| Jun 2023 | - | -$22.35M(+10.4%) | -$101.98M(+4.3%) |
| Mar 2023 | - | -$20.25M(-52.2%) | -$97.78M(+1.2%) |
| Dec 2022 | -$96.62M(+92.7%) | -$42.34M(+148.3%) | -$96.62M(+34.9%) |
| Sep 2022 | - | -$17.05M(-6.1%) | -$71.63M(+3.5%) |
| Jun 2022 | - | -$18.15M(-4.9%) | -$69.19M(+17.3%) |
| Mar 2022 | - | -$19.09M(+10.0%) | -$58.99M(+17.6%) |
| Dec 2021 | -$50.15M(+41.3%) | -$17.35M(+18.8%) | -$50.15M(+9.6%) |
| Sep 2021 | - | -$14.61M(+83.7%) | -$45.77M(+41.0%) |
| Jun 2021 | - | -$7.95M(-22.4%) | -$32.46M(-7.2%) |
| Mar 2021 | - | -$10.25M(-21.0%) | -$34.99M(-1.5%) |
| Dec 2020 | -$35.49M(-26.1%) | -$12.97M(+901.8%) | -$35.54M(+16.4%) |
| Sep 2020 | - | -$1.29M(-87.6%) | -$30.54M(-28.1%) |
| Jun 2020 | - | -$10.47M(-3.0%) | -$42.47M(+3.0%) |
| Mar 2020 | - | -$10.80M(+35.4%) | -$41.25M(-14.1%) |
| Dec 2019 | -$48.01M(+15.0%) | -$7.97M(-39.7%) | -$48.01M(+19.9%) |
| Sep 2019 | - | -$13.23M(+43.0%) | -$40.04M(-31.5%) |
| Jun 2019 | - | -$9.25M(-47.3%) | -$58.46M(-30.8%) |
| Mar 2019 | - | -$17.56M(-44.5%) | -$84.52M(+9.5%) |
| Dec 2018 | -$41.75M(-18.6%) | - | - |
| Sep 2018 | - | -$31.65M(-10.3%) | -$77.17M(+50.5%) |
| Jun 2018 | -$51.30M(+190.3%) | -$35.30M(+661.7%) | -$51.28M(+135.1%) |
| Mar 2018 | - | -$4.63M(-16.9%) | -$21.81M(-1.4%) |
| Dec 2017 | - | -$5.58M(-3.2%) | -$22.13M(+34.6%) |
| Sep 2017 | - | -$5.76M(-1.2%) | -$16.43M(-7.0%) |
| Jun 2017 | -$17.67M(-15.0%) | -$5.83M(+17.7%) | -$17.67M(-1.7%) |
| Mar 2017 | - | -$4.95M(-4523.2%) | -$17.97M(+0.4%) |
| Dec 2016 | - | $112.00K(-101.6%) | -$17.90M(-22.3%) |
| Sep 2016 | - | -$7.00M(+14.1%) | -$23.03M(+10.7%) |
| Jun 2016 | -$20.79M(-384.7%) | -$6.13M(+25.7%) | -$20.79M(+5.9%) |
| Mar 2016 | - | -$4.88M(-2.8%) | -$19.64M(+0.2%) |
| Dec 2015 | - | -$5.02M(+5.4%) | -$19.60M(+6.0%) |
| Sep 2015 | - | -$4.76M(-4.3%) | -$18.48M(-353.0%) |
| Jun 2015 | $7.30M(-157.7%) | -$4.98M(+2.8%) | $7.30M(-14.1%) |
| Mar 2015 | - | -$4.84M(+24.1%) | $8.50M(-25.1%) |
| Dec 2014 | - | -$3.90M(-118.6%) | $11.35M(-4.3%) |
| Sep 2014 | - | $21.02M(-655.8%) | $11.86M(-193.7%) |
| Jun 2014 | -$12.65M | -$3.78M(+89.9%) | -$12.65M(+0.3%) |
| Mar 2014 | - | -$1.99M(-41.2%) | -$12.62M(-4.3%) |
| Dec 2013 | - | -$3.39M(-2.8%) | -$13.18M(+8.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2013 | - | -$3.49M(-6.9%) | -$12.19M(+10.4%) |
| Jun 2013 | -$11.04M(-51.5%) | -$3.75M(+46.4%) | -$11.04M(-53.9%) |
| Mar 2013 | - | -$2.56M(+6.9%) | -$23.95M(+0.3%) |
| Dec 2012 | - | -$2.40M(+2.6%) | -$23.88M(-37.4%) |
| Sep 2012 | - | -$2.33M(-86.0%) | -$38.13M(+1.8%) |
| Jun 2012 | -$22.78M(+315.8%) | -$16.66M(+568.8%) | -$37.47M(+96.3%) |
| Mar 2012 | - | -$2.49M(-85.0%) | -$19.09M(+1.0%) |
| Dec 2011 | - | -$16.64M(+894.1%) | -$18.89M(+316.3%) |
| Sep 2011 | - | -$1.67M(-197.5%) | -$4.54M(-17.2%) |
| Jun 2011 | -$5.48M(-144.1%) | $1.72M(-174.8%) | -$5.48M(-194.8%) |
| Mar 2011 | - | -$2.29M(+0.4%) | $5.78M(-4.2%) |
| Dec 2010 | - | -$2.29M(-12.5%) | $6.03M(-33.4%) |
| Sep 2010 | - | -$2.61M(-120.1%) | $9.06M(-27.1%) |
| Jun 2010 | $12.42M(<-9900.0%) | $12.97M(-736.0%) | $12.42M(+795.9%) |
| Mar 2010 | - | -$2.04M(-377.2%) | $1.39M(-59.7%) |
| Dec 2009 | - | $736.00K(-1.5%) | $3.44M(+61.3%) |
| Sep 2009 | - | $747.00K(-61.6%) | $2.13M(-8987.5%) |
| Jun 2009 | -$24.00K(-100.0%) | $1.94M(>+9900.0%) | -$24.00K(-100.0%) |
| Mar 2009 | - | $14.00K(-102.5%) | -$56.72M(-9.0%) |
| Dec 2008 | - | -$571.00K(-59.5%) | -$62.31M(-9.3%) |
| Sep 2008 | - | -$1.41M(-97.4%) | -$68.67M(-3.8%) |
| Jun 2008 | -$71.36M(+166.0%) | -$54.75M(+880.8%) | -$71.36M(+32.3%) |
| Mar 2008 | - | -$5.58M(-19.4%) | -$53.93M(+11.7%) |
| Dec 2007 | - | -$6.93M(+68.9%) | -$48.29M(-3.2%) |
| Sep 2007 | - | -$4.10M(-89.0%) | -$49.86M(+10.9%) |
| Jun 2007 | -$26.82M(+41.4%) | -$37.32M(<-9900.0%) | -$44.97M(+23.6%) |
| Mar 2007 | - | $65.00K(-100.8%) | -$36.38M(+0.8%) |
| Dec 2006 | - | -$8.50M(-1175.4%) | -$36.09M(+34.1%) |
| Sep 2006 | - | $790.40K(-102.8%) | -$26.92M(-1.5%) |
| Jun 2006 | -$18.98M(+101.1%) | -$28.73M(-8264.7%) | -$27.33M(+100.5%) |
| Mar 2006 | - | $351.90K(-47.5%) | -$13.63M(-1.4%) |
| Dec 2005 | - | $670.70K(+78.8%) | -$13.82M(-3.6%) |
| Sep 2005 | - | $375.10K(-102.5%) | -$14.33M(-1.5%) |
| Jun 2005 | -$9.44M(+57.4%) | -$15.03M(-9470.5%) | -$14.56M(+143.3%) |
| Mar 2005 | - | $160.40K(-0.9%) | -$5.98M(-1.4%) |
| Dec 2004 | - | $161.80K(+7.4%) | -$6.07M(-1.5%) |
| Sep 2004 | - | $150.70K(-102.3%) | -$6.16M(-1.4%) |
| Jun 2004 | -$6.00M(+77.1%) | -$6.46M(-8954.7%) | -$6.25M(+81.7%) |
| Mar 2004 | - | $72.90K(+1.5%) | -$3.44M(-1.6%) |
| Dec 2003 | - | $71.80K(+10.6%) | -$3.49M(-1.6%) |
| Sep 2003 | - | $64.90K(-101.8%) | -$3.55M(-1.4%) |
| Jun 2003 | -$3.39M(+164.7%) | -$3.65M(<-9900.0%) | -$3.60M(-7728.4%) |
| Mar 2003 | - | $16.70K(+7.7%) | $47.20K(+54.8%) |
| Dec 2002 | - | $15.50K(+3.3%) | $30.50K(+103.3%) |
| Sep 2002 | - | $15.00K | $15.00K |
| Jun 2002 | -$1.28M(+194.2%) | - | - |
| Jun 2001 | -$434.60K | - | - |
FAQ
- What is EyePoint Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual EBITDA year-on-year change?
- What is EyePoint Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly EBITDA year-on-year change?
- What is EyePoint Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals TTM EBITDA year-on-year change?
What is EyePoint Pharmaceuticals annual EBITDA?
The current annual EBITDA of EYPT is -$129.23M
What is the all time high annual EBITDA for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual EBITDA is $12.42M
What is EyePoint Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, EYPT annual EBITDA has changed by -$60.23M (-87.28%)
What is EyePoint Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of EYPT is -$48.34M
What is the all time high quarterly EBITDA for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly EBITDA is $21.02M
What is EyePoint Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, EYPT quarterly EBITDA has changed by -$15.32M (-46.40%)
What is EyePoint Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of EYPT is -$148.59M
What is the all time high TTM EBITDA for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high TTM EBITDA is $12.42M
What is EyePoint Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, EYPT TTM EBITDA has changed by -$66.81M (-81.71%)